Datapoint: J&J Sees Potential Stelara Rival in Alvotech-Teva Biosimilar

Alvotech and Teva this week saw promising clinical trial results for their biosimilar to Stelara, Johnson & Johnson’s blockbuster immunology drug. The trial, which compared Stelara and candidate AVT04, found “no clinically meaningful differences in safety” between the two IL-12 and IL-23 inhibitors. Stelara launched in 2009 as a therapy for moderate to severe plaque psoriasis, and has since expanded across the immunology space. For the treatment of psoriasis, virtually all insured lives (99%) have covered or better access to Stelara under the pharmacy benefit. About 40% of covered lives have preferred access to Stelara, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 5/25/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 23

Datapoint: Skyrizi Scores Crohn’s Disease Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 22

Datapoint: Merck-Seagen Deal Could Be in the Works

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 21

Datapoint: Centene Settles New Mexico Medicaid Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today